This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ellodi Pharmaceuticals, L.p.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: James Nezamis: Innovator in Eosinophilic Esophagitis Treatment
Introduction
James Nezamis is a notable inventor based in Blue Bell, PA (US). He has made significant contributions to the field of medicine, particularly in the treatment of eosinophilic esophagitis. His innovative approaches aim to improve patient outcomes while minimizing side effects.
Latest Patents
James Nezamis holds a patent for "Methods of treating eosinophilic esophagitis and reducing candidiasis." This patent discloses methods for treating eosinophilic esophagitis with corticosteroids. The techniques outlined in his patent result in reduced corticosteroid side effects, such as candidiasis. The patent includes details on dosages, formulations, and methods for the administration of corticosteroids.
Career Highlights
Nezamis is currently associated with Ellodi Pharmaceuticals, L.P., where he continues to work on innovative treatments. His expertise in the field has positioned him as a valuable asset to the company and the medical community.
Collaborations
Some of his coworkers include Peter Richardson and Mark Marino, who contribute to the collaborative efforts at Ellodi Pharmaceuticals.
Conclusion
James Nezamis is a pioneering inventor whose work in treating eosinophilic esophagitis showcases his commitment to advancing medical science. His contributions are vital for improving treatment options and patient care.